Actively Recruiting
Randomized Study to Evaluate Safety and Effectiveness of ML-007C-MA for Treating Hallucinations and Delusions in Alzheimers Disease Psychosis
Led by MapLight Therapeutics · Updated on 2026-09-30
300
Participants Needed
62
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of ML-007C-MA in adults aged 55 to 90 years who experience hallucinations and delusions associated with Alzheimers Disease Psychosis ADP. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare ML-007C-MA with a placebo to see how well it treats these symptoms, as measured by the Neuropsychiatric Inventory-Clinician NPI-C Hallucinations and Delusions score. Participants will receive either ML-007C-MA, dosed as 1051.5 mg twice daily or 2103 mg twice daily, or placebo tablets. The study uses a parallel design and the treatment period lasts 7 weeks. The main focus is to observe changes from the start to the end of treatment in hallucinations and delusions scores, along with other secondary measures related to agitation, aggression, and clinical global impressions. During the study, participants will be closely monitored through assessments including the NPI-C HD score at baseline and after 7 weeks of treatment. Additional evaluations include clinical global impressions and agitationaggression scores for some participants. The study involves regular check-ins to track symptom changes and adherence to the treatment. Participants remain under careful medical observation throughout, with the study concluding in December 2027.
CONDITIONS
Brief Title
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Research Team
C
Clinical Trials Contact Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here